CREBBP and precursor B-cell acute lymphoblastic leukemia: Amongst others, alterations in IKZF1, TP53-, CDKN2A, CREBBP, NR3C2, MSH6, PRPS1, PRPS2, NT5C2 are ETV6 are associated with unfavorable outcome and/or therapy resistance in B-ALL [400,401,402,403].